CD40 and ovarian cancer: Indeed, tumor-associated moDCs express druggable CD40 in MC38 tumors, as well as human ovarian cancer ascites.32 We show that monocyte-derived APC can be targeted with an agonistic anti-CD40 antibody to support anti-tumor CD8+ T-cell responses and subsequent tumor regression.